Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$125.91 USD

125.91
873,688

-1.07 (-0.84%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $125.97 +0.06 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.

Myriad Genetics (MYGN) Announces Favorable Research Results

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

DaVita HealthCare (DVA) Up 12% Since Last Earnings Report: Can It Continue?

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Encompass Health (EHC) Up 5.3% Since Last Earnings Report?

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.

Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics

Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Urmimala Biswas headshot

3 Medtech Stocks Likely to Top Estimates This Earnings Season

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

Strength of the base business bodes well for Quest Diagnostics (DGX).

Quest Diagnostics (DGX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Quest Diagnostics (DGX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Quest Diagnostics (DGX) Q4 Revenues Top, Gross Margin Down

Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the fourth quarter of 2023.

Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Advances in Cancer Research With New Deal

Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.

Oncology Space Gains Momentum: 3 Stocks in Focus

Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.

Riya Anand headshot

3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024

Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.

Quest Diagnostics (DGX) and Fitbit Team Up for New Pilot Study

Quest Diagnostics (DGX) partners with Fitbit to study the potential of wearable devices to improve metabolic health.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.